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IMPORTANCE In critically ill patients with altered consciousness, continuous
electroencephalogram (cEEG) improves seizure detection, but is resource-consuming
compared with routine EEG (rEEG). It is also uncertain whether cEEG has an effect
on outcome.
OBJECTIVE To assess whether cEEG is associated with reduced mortality compared with rEEG.
DESIGN, SETTING, AND PARTICIPANTS The pragmatic multicenter Continuous EEG Randomized
Trial in Adults (CERTA) was conducted between 2017 and 2018, with follow-up of 6 months.
Outcomes were assessed by interviewers blinded to interventions.The study took place at
4 tertiary hospitals in Switzerland (intensive and intermediate care units). Depending on
investigators’ availability, we pragmatically recruited critically ill adults having Glasgow Coma
Scale scores of 11 or less or Full Outline of Responsiveness score of 12 or less, without
recent seizures or status epilepticus. They had cerebral (eg, brain trauma, cardiac arrest,
hemorrhage, or stroke) or noncerebral conditions (eg, toxic-metabolic or unknown etiology),
and EEG was requested as part of standard care. An independent physician provided
emergency informed consent.
INTERVENTIONS Participants were randomized 1:1 to cEEG for 30 to 48 hours vs 2 rEEGs
(20 minutes each), interpreted according to standardized American Clinical Neurophysiology
Society guidelines.
MAIN OUTCOMES AND MEASURES Mortality at 6 months represented the primary outcome.
Secondary outcomes included interictal and ictal features detection and change in therapy.
RESULTS We analyzed 364 patients (33% women; mean [SD] age, 63 [15] years). At 6 months,
mortality was 89 of 182 in those with cEEG and 88 of 182 in those with rEEG (adjusted
relative risk [RR], 1.02; 95% CI, 0.83-1.26; P = .85). Exploratory comparisons within subgroups
stratifying patients according to age, premorbid disability, comorbidities on admission,
deeper consciousness reduction, and underlying diagnoses revealed no significant effect
modification. Continuous EEG was associated with increased detection of interictal features
and seizures (adjusted RR, 1.26; 95% CI, 1.08-1.15; P = .004 and 3.37; 95% CI, 1.63-7.00;
P = .001, respectively) and more frequent adaptations in antiseizure therapy (RR, 1.84;
95% CI, 1.12-3.00; P = .01).
CONCLUSIONS AND RELEVANCE This pragmatic trial shows that in critically ill adults with
impaired consciousness and no recent seizure, cEEG leads to increased seizure detection and
modification of antiseizure treatment but is not related to improved outcome compared with
repeated rEEG. Pending larger studies, rEEG may represent a valid alternative to cEEG in
centers with limited resources.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03129438.
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E lectroencephalography (EEG) allows identificationof subclinical seizures and status epilepticus (SE) inintensive care unit (ICU) patients,1-4 treatment adjust-
ment under general anesthesia,5 is part of prognostication
after cardiac arrest,6,7 and identifies cerebral ischemia follow-
ing subarachnoid hemorrhage.8 Continuous EEG (cEEG) de-
tects seizure activity4 and nonconvulsive SE9 more effi-
ciently than routine EEG (rEEG; 20 minutes) and is gaining
increasing popularity.10-13 Both European Society of Inten-
sive Care Medicine1 and American Clinical Neurophysiology
Society2,3 suggest cEEG for critically ill patients with altered
consciousness.3 However, only low-quality evidence sup-
ports these recommendations,1,3 which may also be difficult
to apply in centers lacking human and technical resources.1,3,12
There are significant associations between time spent with
seizures or SE and worse clinical prognosis in critically ill
children14 and adults.15 Two adult observational studies sug-
gest that cEEG may be associated with better outcome: among
40 000 patients, lower mortality was found in those under-
going cEEG (25%) vs rEEG (39%; adjusted odds ratio [OR], 0.63;
95% CI, 0.52-0.76).10 Another observation on 7 million pa-
tients showed lower mortality among the 22 000 with cEEG
(23%) vs no EEG or rEEG (28%; adjusted OR, 0.83; 95% CI, 0.75-
0.92) at the expense of higher costs and hospital length.12 Both
cross-sectional analyses were retrospective and relied on
sampling from discharge diagnoses, implying potential risks
of inclusion and information biases, therefore limiting con-
clusions on causality of associations. Indeed, other studies did
not confirm these findings: 234 patients undergoing cEEG had
longer hospitalizations and more frequent anticonvulsant pre-
scription modifications but no mortality difference com-
pared with controls without EEG.16 Prolonged EEG did not cor-
relate with better outcome in 29 elderly patients with
nonconvulsive SE compared with 58 control patients under-
going repeated rEEG.17 After cardiac arrest, cEEG prognostic
yield seems similar to repeated rEEG,18 with no trend toward
a different outcome.19
Thus, the issue of whether cEEG vs rEEG improves pa-
tients’ outcome remains controversial.20 This trial’s aim was to
evaluate whether cEEG is associated with reduced mortality.
Methods
Study Design
This was a Swiss multicenter (Centre Hospitalier Universi-
taire Vaudois in Lausanne, Hôpital de Sion, Inselspital Bern,
and Universitätsspital Basel), pragmatic, randomized clinical
trial to evaluate the prognostic yield of cEEG, with nationally
coordinated approval by local ethic commissions (project-ID
2017-00268). Inpatients older than 18 years in intensive or in-
termediate care units having impaired consciousness of any
etiology, defined as a Glasgow Coma Scale (GCS) score of 11 or
less or a Full Outline of Responsiveness (FOUR) score of 12 or
less21,22 verified immediately before randomization, referred
from the treating team for EEG, were recruited during local in-
vestigators’ availability (working hours, not on weekends).
Electroencephalogram requests reflected standard clinical
practice in the participating hospitals. We excluded patients
in palliative care, those risking invasive procedures within
48 hours, and those with recent seizures (36 hours) or SE
(96 hours before randomization): it was determined unethi-
cal to prevent patients from cEEG to monitor refractory SE treat-
ment. Interventions were started after written approval by a
physician unrelated to patient care or the study, then written
proxy consent was obtained at 7 ±3 days; written patient’s con-
sent was sought in survivors regaining intellectual capability.
Further methodologic details were previously published.23
The formal trial protocols can be found in Supplement 1.
Intervention
Patients were randomized 1:1 through an online program
accessible constantly to 1 cEEG or 2 rEEG, stratified by site
(eFigure 1 in Supplement 2). Masking to the caring team was
impossible owing to the intervention type; however, patients
were not aware of the EEG length. All were recorded with video
EEG (NicOne; Viasys Neurocare) started within 4 hours after
randomization (which occurred immediately after request),
using 21 to 23 electrodes following the international 10 to 20
system; reduced montages with at least 11 electrodes were pos-
sible in neurosurgical patients,24,25 following technical re-
quirements for EEG recordings in this setting.26 Continuous
EEG lasted 30 to 48 hours; cEEG interruptions less than 2 hours
were allowed for diagnostic purposes (eg, neuroimaging). Pa-
tients randomized to rEEG had two 20- to 30-minute record-
ings over 48 hours (no repetition within the same day). Stan-
dardized reactivity testing with loud sounds and axial
nociceptive stimulations was performed at least twice daily.27
All EEG interpreters were certified for the American Clini-
cal Neurophysiology Society Standardized Critical Care EEG
Terminology.28-30 Results were communicated to treating
teams within 2 hours of EEG start, at least 3 (working days) or
2 times per day (weekends and bank holidays). A uniform op-
erational definition of electrographic seizures (≥10 seconds)
and SE (≥5 minutes) was used: repetitive, rhythmic, or peri-
odic discharges or spike-waves at greater than 3 Hz or at less
than 3 Hz with evolution in amplitude, frequency, location, or
with electroclinical response to antiseizure drugs (ASD).4,28,31,32
The protocolled EEG intervention was stopped in patients di-
agnosed as having seizures or SE during the intervention pe-
riod (up to 48 hours); they were subsequently treated accord-
ing to best practice, allowing conversion to cEEG if needed.
Key Points
Question In patients with acute consciousness impairment and
no recent seizures, does continuous electroencephalogram (cEEG)
correlate with reduced mortality compared with repeated routine
EEG (rEEG)?
Findings In this pragmatic, multicenter randomized clinical trial
analyzing 364 adults, cEEG translated into a higher rate of
seizures/status epilepticus detection and antiseizure treatment
modifications but did not improve mortality compared with rEEG.
Meaning Pending larger studies, rEEG may represent a valid
alternative to cEEG in centers with limited resources.
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Variables and Outcomes
We prospectively recorded demographics, estimated modi-
fied Rankin Scale (mRS) score before admission, admission rea-
son, comorbidities (Charlson Comorbidity Index [CCI]),33 pre-
vious epileptic seizures, GCS, or FOUR immediately before EEG
intervention, medication during intervention, and adverse
events possibly related to intervention. Results are presented
according to the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) reporting guideline.
Mortality at 6 months represented the primary outcome.
We assessed secondary outcomes during hospital stay and
through semistructured telephone interviews with patients,
relatives, or treating physicians34 at 4 weeks and 6 months,
blinded to intervention. They focused on:
• Midazolam/propofol and ASD prescription at EEG start
• Seizure/SE detection
• Detection of interictal, potentially epileptiform features,
including periodic or rhythmic patterns35 (excluding gener-
alized anterior rhythmic delta36)
• Modification of ASD or sedation (either started, stopped,
increased, or decreased), triggered by the EEG results
according to treating physicians, occurring over 60 hours
following the beginning of the recording; not standardized
(pragmatic study)
• Need of additional EEG after the intervention
• Rate of in-hospital infections requiring antibiotics
• Mechanical ventilation duration
• Time to death from randomization
• Hospitalization length in survivors
• mRS; Cerebral Performance Category (CPC)37 at 6 months.
We also assessed destination after discharge, ability to
return to work, and hospitalization costs; these will be the
subject of subsequent studies. This trial was not designed to
investigate EEG for delayed ischemia.
Statistical Analysis
We used Stata, version 14 (StataCorp). The sample size for the
primary outcome was calculated23 using data available dur-
ing the study conception: mortality in patients undergoing
cEEG patients 14% lower than in those with no cEEG (25% vs
39%)10; 2 × 174 patients were needed to detect this difference
(2-sided test with 0.8 power; .05 α error; χ2 for independent
samples). A safety interim analysis of the primary outcome was
planned after 100 patients, foreseeing a study interruption if
the target difference in primary outcome would have been met:
in June 2018, recruitment was continued (cEEG n = 28 of 55;
rEEG, n = 27 of 55; P = .85, χ2).
Analysis of secondary end points23 was performed using
χ2, 2-sided Fisher, t, or Mann-Whitney U tests as needed. The
primary outcome, assessed for patients with available data at
6 months and most relevant secondary outcomes, calculated
for all patients with available data, were also assessed with risk
ratios (dichotomous variables) and linear regressions (con-
tinuous variables). The relative risk (RR) for death at 6 months
associated with cEEG was estimated by Poisson regression with
robust error variance. For continuous variables, linear regres-
sion was performed to calculate coefficients. For exploratory
purposes, regressions were adjusted for potential confound-
ers (variables with marked asymmetry across intervention
groups despite randomization). We also explored the pri-
mary outcome in subgroups of patients with the most preva-
lent neurologic diagnoses, and patients with deeper conscious-
ness impairment (FOUR ≤10 or GCS ≤8). Therefore, interaction
terms were fit to the regression models evaluating relative
death risks at 6 months and use of cEEG, to assess effect modi-
fication by age, mRS, CCI, hypoxic-ischemic encephalopathy,
brain trauma, and intracranial hemorrhage. Significance was
set at P = .05, with 2-sided approaches.
Results
Between April 2017 and November 2018, we recruited 402 pa-
tients; 6 were excluded before intervention (5 double inclu-
sions and 1 death) and 28 during or shortly thereafter (27 proxy
or post hoc consent refusals and 1 double inclusion); 183 par-
ticipants in the rEEG and 185 in the cEEG were available for out-
come assessments. Four patients were lost to follow-up, re-
sulting in 182 participants in each arm available for the primary
outcome at 6 months (Figure 1). All patients received the EEG
intervention to which they were randomized. No adverse event
related to EEG procedures was observed.
Table 1 summarizes baseline characteristics; interven-
tion groups appeared globally balanced, but patients receiv-
ing rEEG tended to have a lower burden of comorbidities, less
prevalent hypoxic-ischemic encephalopathy and brain trauma,
and more prevalent ischemic stroke, toxic metabolic disor-
ders, and other conditions (infections, inflammations, onco-
logical, and/or degenerative). Median EEG duration was in line
Figure 1. Study Flowchart
402 Randomized patients
201 Allocated to rEEG 201 Allocated to cEEG
1 Excluded (death
before EEG start)
5 Excluded
(double inclusions)
200 Received rEEG 196 Received cEEG
17 Excluded (proxy 
or post hoc consent 
refusals)
11 Excluded
10
1
Proxy or post hoc
consent refusals
Double inclusion
183 Included in intention 
to rEEG analysis
185 Included in intention 
to cEEG analysis
1 Lost to follow-up 3 Lost to follow-up
182 Included in primary 
outcome analysis
182 Included in primary 
outcome analysis
The number of screened patients was not recorded. cEEG indicates continuous
electroencephalogram; rEEG, routine EEG.
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with the protocol (40 minutes for rEEG [2 × 20 minutes]; 32
hours for cEEG). No relevant difference was observed across
centers for demographics, anoxic-ischemic encephalopathy,
and time to EEG (data not shown).
Table 2 illustrates outcomes at 6 months. Mortality did not
differ across intervention groups and centers (Le Centre Hos-
pitalier Universitaire Vaudois: n = 147 of 287; other hospitals,
n = 40 of 97; P = .91; χ2). This did not change after adjusting
for CCI and hypoxic-ischemic encephalopathy nor after ex-
ploratory stratification for hypoxic-ischemic encephalopa-
thy (eTable in Supplement 2), or age, baseline mRS, CCI, trau-
matic brain injury, intracranial hemorrhage, severity of
consciousness impairment, or time to EEG (Figure 2). Limit-
ing analysis to survivors, CPC did not change across groups,
while mRS evolution at 6 months was better in the rEEG group,
especially in patients without hypoxic-ischemic encephalopa-
thy; eFigure 2 in Supplement 2 shows the distribution of func-
tional outcomes.
Table 3 outlines exploratory secondary outcomes accord-
ing to intention-to-monitor during the EEG intervention (if an
rEEG was converted to cEEG and the patient quit interven-
tion; results of the latter and subsequent treatment were not
counted for this analysis). Detection of features of ictal-
interictal continuum, seizures, and/or SE were more frequent
in the cEEG group, as was the modification rate of ASD pre-
scription; conversely, sedatives, need for EEG after interven-
tion, infections, mechanical ventilation duration, time to death
since randomization, and survivors’ length of stay did not dif-
fer. To explore whether cEEG facilitated decisions of life-
sustaining treatment withdrawal, we further analyzed death
latency, which was comparable in the subgroup with hypoxic-
ischemic encephalopathy (rEEG: median, 8.5 days; range,
0-156; cEEG: median, 6 days; range, 0-157; P = .07) and with-
out (rEEG: median, 11 days; range, 1-130; cEEG: median, 8 days;
range 1-176; P = .40; U tests).
Discussion
To our knowledge, this represents the first randomized clini-
cal trial in this clinical setting. It reveals similar long-term mor-
tality in critically ill adults with altered consciousness with-
out recent seizures randomized to repeated rEEG or cEEG,
despite higher detection of ictal and interictal EEG features and
ASD modifications in those receiving cEEG.
Patients were recruited following a quantitative defini-
tion of consciousness impairment, unlike previous
observations.10,12,16 Additionally, they were assessed for
comorbidities and estimated disability before intervention,
allowing evolution characterization over 6 months. This rep-
resents a reasonable estimation of long-term outcome, un-
like mortality at discharge reported previously.10,12,16 In our
view, the principal finding is corroborated by adjustment for
imbalances in baseline characteristics despite randomiza-
tion, exploration of potential effects of demographics and eti-
ologies, and comparable latency to death in both interven-
tions. Median cEEG recording (32 hours) may appear shorter
than the usual duration in some centers, but is longer than a
Table 1. Baseline Patient Characteristics
Characteristic
EEG, No. (%)
Routine
(n = 183)
Continuous
(n = 185)
Female 61 (33.3) 62 (33.5)
Age, mean (SD), y 63.7 (15.3) 63.8 (14.6)
Patient location before hospitalization
Home 139 (76.0) 147 (79.5)
Other acute hospital 35 (19.1) 33 (17.8)
Rehabilitation clinic or nursing home 9 (4.9) 5 (2.7)
mRS before admission, median (range) 1 (1-5) 1 (1-4)
Reason of admission
Brain injury (including CA) 102 (55.7) 116 (61.6)
Medical 60 (32.8) 44 (23.8)
Surgical 16 (8.7) 24 (12.4)
Other 5 (2.7) 4 (2.2)
Previous seizures/SE (excluding seizures
≤36 h or SE ≤96 h before randomization)
19 (10.4) 15 (8.1)
SAPS II before EEG intervention,
median (range)
50 (8-94) 52 (6-89)
FOUR before EEG intervention,
median (range)
4 (0-15) 5 (0-15)
GCS before EEG, median (range) 3 (3-11) 3 (3-11)
CCI before EEG, median (range) 1 (0-10) 1 (0-12)
Patient location during EEG intervention
Intensive care unit 169 (92.4) 177 (95.7)
Intermediate care unit 11 (6.0) 6 (3.2)
General ward 3 (1.6) 2 (1.1)
Final neurologic diagnosis
Hypoxic-ischemic encephalopathy 53 (28.9) 60 (32.4)
Brain trauma 17 (9.3) 32 (17.3)
Intracranial hemorrhage 40 (21.9) 47 (25.4)
Ischemic stroke 18 (9.8) 10 (5.4)
Toxic-metabolic, not primarily involving
brain
14 (7.7) 9 (4.9)
Other 41 (22.4) 27 (14.6)
Time of EEG after admission,
median (range), h
60.3
(1.0-890.0)
57.5
(0.7-2116.7)
EEG duration during intervention,
mean (SD), min
40 (9.2) 1925 (792)
ASD administration at first EEG starta 56 (30.6) 67 (36.2)
LEV 35 (19.1) 51 (27.6)
VPA 11 (6.0) 13 (7.0)
LCM 5 (2.7) 12 (6.5)
BRV 1 (0.5) 2 (1.0)
PHT 0 2 (1.0)
Propofol administration at first EEG start 95 (51.9) 102 (55.1)
Dose in patients under propofol,
median (range), mg/kg/h
1.00
(0.01-4.02)
0.70
(0.01-3.93)
Midazolam administration at 1st EEG start 78 (42.6) 70 (37.8)
Dose in patients under midazolam,
median (range), mg/kg/h
0.086
(0.001-2.64)
0.075
(0.001-0.963)
Abbreviations: ASD, antiseizure drug; BRV, brivaracetam; CA, cardiac arrest;
CCI, Charlson Comorbidity Index; EEG, electroencephalogram; FOUR, Full
Outline of Responsiveness score; GCS, Glasgow Coma Scale score;
mRS, modified Rankin Scale; LEV, levetiracetam; LCM, lacosamide;
PHT, phenytoin; SAPS II, Simplified Acute Physiology Score; SE, status
epilepticus; VPA, valproate.
a Combinations are possible; other ASD included clonazepam, diazepam,
gabapentin, ketamine, lamotrigine, lorazepam, oxazepam, perampanel,
pregabalin, rufinamide, and topiramate.
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retrospective evaluation from 3 large US hospitals38 and in line
with a 2018 Dutch survey13; as opposed to that assessment, all
our recordings had concomitant video. Notably, the 2 dis-
charge-based studies did not report on cEEG duration10,12 and
93% of seizures seem to be detectable within 24 to 48 hours.4
Overall mortality (48.6%) was higher than in the 2 retro-
spective observations (22% and 39%10,12), possibly reflecting
enrollment of 30.7% hypoxic-ischemic patients, a condition
related to 50% mortality. Also, exclusion from analysis (per
Swiss law) of survivors subsequently withdrawing patient con-
sent inflated our mortality rate (mortality would have been
45.4% considering these 26 patients). Because previous stud-
ies do not detail on diagnoses, direct comparisons are impos-
sible. Additionally, those studies assessed mortality at dis-
charge, potentially underestimating it at 6 months. Finally,
a randomized study appears different from retrospective
assessments of discharge diagnoses.
Mortality in patients without cardiac arrest showed a non-
significant trend favoring cEEG: the absolute difference of 4.5%
lies at less than the targeted 14% but is similar to the 5%
reported in the 2019 retrospective assessment.12 This might
orient on the sample size needed for a future trial, where a dif-
Table 2. Primary Outcome (Mortality at 6 Months) and Functional Outcomes Across cEEG vs rEEG (Poisson Regression Models
for Categorical Variables [Mortality] and Linear Regression Models for Continuous Variables [Δ mRS and CPC])a
Outcome
rEEG (n = 182),
No. (%)
cEEG (n = 182),
No. (%)
Crude Adjusted for CCI, cardiac arrest
Relative risk (95% CI) P value Relative risk (95% CI) P value
Mortality at 6 mo, No. (%) 88 (48.4) 89 (48.9) 1.01 (0.82 to 1.25) .92 1.02 (0.83 to 1.26) .85
Median (range) Median (range) Regression coefficient P value Regression coefficient P value
Δ mRS at 6 mo, survivors 1 (−5 to 4) 1 (−3 to 5) 0.65 (0.13 to 1.16) .01 0.63 (0.13 to 1.14) .01
CPC at 6 mo, survivors 2 (1 to 4) 2 (1 to 4) 0.08 (−0.17 to 0.34) .52 0.08 (−0.18 to 0.33) .55
Abbreviations: CCI, Charlson Comorbidity Index; cEEG, continuous
electroencephalography; CPC, cerebral performance category;
Δ mRS, evolution of modified Rankin Scale between prehospitalization and at
6 months; rEEG, routine electroencephalography.
a Results given as crude, and adjusted for hypoxic-ischemic encephalopathy and
CCI. P values less than .05 are significant.
Figure 2. Effect Modification Regarding the Relative Risk of Mortality at 6 Months
for Continuous Electroencephalogram (EEG)
Favors
continuous
EEG
Favors
routine
EEG
0.1 31
Relative risk for mortality
at 6 mo (95% CI)
Relative risk for
mortality at 6 mo
(95% CI)
P value for
interactionGroups
Total cohort with follow-up
at 6 mo (n = 364)
1.01 (0.82-1.25)
Age, y
≥65 0.91 (0.72-1.13)
<65 1.23 (0.80-1.88)
.21
mRS at admission
0-2 0.99 (0.78-1.26)
>2 1.15 (0.74-1.80)
.55
Charlson comorbidity index
0 1.32 (0.73-2.38)
> 0 1.01 (0.81-1.27)
.40
Hypoxic-ischemic encephalopathy
Without 0.90 (0.68-1.20)
With 1.17 (0.86-1.58)
.23
Traumatic brain injury  
Without 1.04 (0.84-1.24)
With 1.10 (0.44-2.71)
.91
≤8 and/or FOUR ≤10 1.02 (0.83-1.26)
With GCS
>8 and/or FOUR >10 0.36 (0.05-2.85)
.32
With hospital stay
≤1 wk 1.11 (0.88-1.41)
>1 wk 0.70 (0.44-1.12)
.09
Intracranial hemorrhage
Without 1.05 (0.83-1.33)
With 0.89 (0.55-1.43)
.53
FOUR indicates Full Outline of
Responsiveness score; GCS, Glasgow
Coma Scale score; mRS, modified
Rankin Scale.
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ference of 4% (for example, a decrease from 48% to 44%) would
imply enrollment of 4872 analyzable patients without car-
diac arrest (2-sided proportion test; P = .05; power = 0.8). The
fact that disability (mRS) evolved more favorably in survivors
without cardiac arrest undergoing rEEG seems to counterbal-
ance the mortality tendency.
This trial confirms that cEEG leads to increased detection
of ictal and interictal EEG features than rEEG, even excluding
patients with recent seizures or SE. The rEEG detection rate
(4.4% over 40 minutes) represents roughly one-quarter of cEEG
(15.7% over 32 hours in median); the latter is comparable with
literature data from the past few years (2017-2019),38,39 also
including patients after cardiac arrest, and suggests reason-
able generalizability of our findings. The observational cEEG
study identified ictal changes in 12.3% to 13.6%,38 the meta-
analysis in 6.3% of rEEG and 15.6% of cEEG.39 The pooled
prevalence of repetitive or rhythmic features of the ictal-
interictal continuum, excluding generalized rhythmic delta,
was between 28% to 29% in 3 US centers38 and 4% to 9% for
rEEG and 7% to 15% for cEEG in the meta-analysis.39 These
broad proportions appear lower than ours (55.7% for rEEG and
69.2% for cEEG), possibly following inclusion of sporadic epi-
leptiform features in our labeling, and maybe higher assess-
ment accuracy; all our interpreters were American Clinical Neu-
rophysiology Society certified, strengthening external validity.
One-third of patients received ASD at EEG start, reflect-
ing prophylaxis following brain trauma and the fact that about
10% of participants had previous seizures (before the time-
frame defined as exclusion criterium). Antiseizure drug pre-
scription was modified more frequently in the cEEG arm, likely
following the refined diagnosis of interictal and ictal changes
compared with rEEG. The modification rate (21%; 28% if
including changes in sedation) appears lower than reported in
previous observational studies.16,40 However, those modifi-
cations occurred during the entire hospitalization, as op-
posed to our time restriction over the first 60 hours after EEG
start and the definition of association with EEG results, which
should better (although more conservatively) reflect the ef-
fect of the EEG intervention.
Improved diagnostics and increased modification in ASD
do not seem to translate into better clinical outcome (not only
mortality but also functional) nor different hospitalization
length in survivors. One possible explanation is that EEG may
trigger decisions to life-sustaining treatment withdrawal. This
would rather involve both arms (background is the most in-
formative feature in this context25). Mortality and mRS evo-
lution in survivors were actually not different between inter-
vention groups considering patients with cardiac arrest (where
EEG is an integral part of these decisions41); furthermore, pre-
vious studies did not show any mortality difference in this par-
ticular diagnosis across EEG durations.19,42 Also, although un-
fortunately we do not have information on death causes, death
latency was relatively similar across EEG types in the whole
cohort (median: 1 week after intervention); a massive effect of
active withdrawal seems unlikely. Another potential explana-
tion may involve underlying cerebral structural damage inde-
pendently from the additional role played by epileptic phe-
nomena. As illustrated for patients with SE, successful
treatment of electrical dysfunction may be futile if the effects
of initial structural injury are predominant.43,44 This might sug-
gest that underlying variables not related to epileptic aspects
may represent additional important determinants of progno-
sis in this setting.
Need of subsequent EEG after the intervention was not sig-
nificantly higher in cEEG, possibly reflecting a higher seizure
and SE detection rate. Sedation at baseline was comparable
across groups and globally given at relatively low dosage, and
EEG-triggered changes were minor; duration of mechanical
ventilation did not differ.
Limitations
This study has limitations. Our sample size is based on the only
available comparison at the time of design (2015-2016), and
analysis of several secondary outcomes may have been un-
derpowered. We enrolled patients with hypoxic-ischemic en-
cephalopathy having a high mortality risk.45 However, they rep-
resent one of the most frequent ICU neurologic diagnoses,46
and some previous observational cEEG studies also included
Table 3. Exploratory Analyses: Associations of Secondary Outcome Measures With EEG Typea
Outcome
No. (%)
Relative risk
(95% CI)
P
value
rEEG
(n = 183)
cEEG
(n = 185)
Features of ictal-interictal continuum detected,
without seizures/SE
102 (55.7) 128 (69.2) 1.24 (1.06-1.46) .009
Seizures/SE detected 8 (4.4) 29 (15.7) 3.59 (1.68-7.64) .001
Changes in antiseizure drug prescription within
60 h following start of EEG interventionb
21 (11.5) 39 (21.1) 1.84 (1.12-3.00) .01
Changes in sedation prescription within 60 h
following start of EEG interventionb
8 (4.4) 13 (7.0) 1.61
(0.683-3.79)
.27
Need of additional EEG after intervention 41 (22.8)c 56 (31.1) 1.37 (0.97-1.93) .08
In-hospital infection requiring antibiotics 56 (30.8) 47 (25.7) 0.82 (0.61-1.11) .20
Length of ventilation need, median (range), h 123 (0-837) 138 (0-1214) NA .47
Length of hospital stay in survivors,
median (range), d
25.3 (2.6-393.3) 24.5 (1.4-161.1) NA .84
Time to death since randomization,
median (range), d
8.5 (0-157) 6 (0-176) NA .07
Abbreviations: cEEG, continuous
electroencephalography; NA, not
applicable; rEEG, routine
electroencephalography; SE, status
epilepticus.
a Relative risk for categorical variables
(ictalinterictal continuum,
seizures/se, changes in antiseizure
drug or sedation treatment, need of
additional EEG, or in-hospital
infection) and U test for continuous
variables (duration of ventilation
support, length of stay in survivors,
or time to death). Values less than
.05 are significant.
b Motivated by EEG results according
to treating physicians.
c Including 5 (2.7%) converted to
cEEG.
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them.10,39 As mentioned, a considerably larger patient sample
without this condition may allow detecting small outcome dif-
ferences. We did not record the start of altered conscious-
ness, but EEG was performed within 4 hours after request (see
Methods). The time of EEG intervention since hospital admis-
sion may seem relatively long, but restricting analysis to pa-
tients admitted less than a week ago does not change the re-
sults. We pragmatically studied a referral cohort. There was
unfortunately no screening of all potential candidates (recruit-
ment occurred only during working hours); we recognize that
this may represent a selection bias. In addition, many pa-
tients received sedation at baseline, which may reduce sei-
zure detection, but doses were globally low and comparable
across groups. Although suboptimal, this reflects clinical
routine; the similarities of our cEEG seizure detection rates to
previous studies seem to corroborate our findings’ generaliz-
ability. The cohort is heterogeneous in terms of etiologies, but
inclusion criteria closely fit current recommendations. We as-
sessed the relation of mortality with a diagnostic test, not a
treatment. However, EEG results were provided regularly and
timely, translating into changes in clinical management. We
excluded patients having seizures or SE immediately before
enrollment, potentially lowering the EEG yield, but it seems
that cEEGs ordered to monitor already-diagnosed SE repre-
sent a minority of requests in clinical practice.38 Our findings
are not generalizable to ICU patients with incident seizures or
SE, in whom cEEG is commonly used for treatment monitor-
ing. The protocol foreseeing communication to the care-
givers several times per day, and recording durations of at least
30 hours, corresponds to clinical practice and actually lies
beyond current recommendations.2
Conclusions
Considering these limitations, despite increased detection rates
of interictal and ictal features and of EEG-driven modifica-
tion of antiseizure therapy, cEEG does not seem to correlate
with improved patient outcome compared with repeated rEEG.
Pending larger studies in a more homogeneous patient popu-
lation, repeated rEEG may represent a reasonable alternative
to cEEG, at least in centers with limited resources.
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